HealthEquity Gestione

Gestione criteri di controllo 3/4

HealthEquity Il CEO è Jon Kessler, nominato in Feb2014, e ha un mandato di 10.75 anni. la retribuzione annua totale è $ 13.45M, composta da 5.2% di stipendio e 94.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.35% delle azioni della società, per un valore di € 28.75M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 7.7 anni.

Informazioni chiave

Jon Kessler

Amministratore delegato

US$13.4m

Compenso totale

Percentuale dello stipendio del CEO	5.2%
Mandato del CEO	10.8yrs
Proprietà del CEO	0.4%
Durata media del management	3yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jon Kessler rispetto agli utili di HealthEquity?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jul 31 2024	n/a	n/a	US$106m
Apr 30 2024	n/a	n/a	US$80m
Jan 31 2024	US$13m	US$700k	US$56m
Oct 31 2023	n/a	n/a	US$29m
Jul 31 2023	n/a	n/a	US$13m
Apr 30 2023	n/a	n/a	-US$8m
Jan 31 2023	US$13m	US$700k	-US$26m
Oct 31 2022	n/a	n/a	-US$59m
Jul 31 2022	n/a	n/a	-US$62m
Apr 30 2022	n/a	n/a	-US$55m
Jan 31 2022	US$10m	US$700k	-US$44m
Oct 31 2021	n/a	n/a	-US$6m
Jul 31 2021	n/a	n/a	US$723k
Apr 30 2021	n/a	n/a	US$4m
Jan 31 2021	US$9m	US$667k	US$9m
Oct 31 2020	n/a	n/a	US$3m
Jul 31 2020	n/a	n/a	-US$20m
Apr 30 2020	n/a	n/a	-US$332k
Jan 31 2020	US$5m	US$500k	US$40m
Oct 31 2019	n/a	n/a	US$53m
Jul 31 2019	n/a	n/a	US$90m
Apr 30 2019	n/a	n/a	US$93m
Jan 31 2019	US$5m	US$483k	US$74m
Oct 31 2018	n/a	n/a	US$67m
Jul 31 2018	n/a	n/a	US$61m
Apr 30 2018	n/a	n/a	US$56m
Jan 31 2018	US$4m	US$400k	US$47m

Compensazione vs Mercato: La retribuzione totale di Jon ($USD 13.45M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 3.50M ).

Compensazione vs guadagni: La retribuzione di Jon è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jon Kessler (56 yo)

10.8yrs

Mandato

US$13,448,018

Compensazione

Mr. Jon Kessler is a Member of the Board of Managers at HealthEquity Advisors, LLC. He has been the Chief Executive Officer and President of HealthEquity, Inc. since February 2014. Mr. Kessler founded Wage...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jon Kessler	President	10.8yrs	US$13.45m	0.35% € 28.7m
Stephen Neeleman	Founder & Vice Chairman	22yrs	US$3.04m	0.94% € 77.0m
James Lucania	CFO & Executive VP	1.2yrs	US$5.23m	0.0086% € 707.7k
Elimelech Rosner	Executive VP & CTO	2.7yrs	US$4.81m	0.0033% € 269.3k
Delano Ladd	Executive VP	8.2yrs	US$2.64m	0.044% € 3.6m
Richard Putnam	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Steve Lindsay	Executive Vice President of Sales & Relationship Management	3.3yrs	Nessun dato	Nessun dato
Brad Bennion	Executive Vice President of Corporate Development & Strategy	7.6yrs	Nessun dato	Nessun dato
Tia Padia	Executive VP & Chief Marketing Officer	2.8yrs	Nessun dato	Nessun dato
Cheryl King	Executive VP & Chief People Officer	1.6yrs	Nessun dato	Nessun dato
Kamesh Tumsi	Senior VP & Head of Product	2yrs	Nessun dato	Nessun dato
Selim Aissi	Executive VP & Chief Security Officer	no data	Nessun dato	Nessun dato

3.0yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di 2HE è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jon Kessler	President	15.7yrs	US$13.45m	0.35% € 28.7m
Stephen Neeleman	Founder & Vice Chairman	22yrs	US$3.04m	0.94% € 77.0m
Adrian Dillon	Independent Director	8.2yrs	US$297.50k	0.062% € 5.1m
Robert Selander	Independent Non-Executive Chairman	9.2yrs	US$362.50k	0.065% € 5.4m
Paul Black	Independent Director	2.2yrs	US$272.50k	0.0050% € 413.0k
Evelyn Dilsaver	Independent Director	10.3yrs	US$290.00k	0.037% € 3.0m
Stuart Parker	Independent Director	3.9yrs	US$280.00k	0.035% € 2.9m
Gayle Wellborn	Independent Director	7.3yrs	US$278.87k	0.017% € 1.4m
Debra McCowan	Independent Director	6.6yrs	US$275.00k	0.012% € 962.3k
Rajesh Natarajan	Independent Director	2.5yrs	US$272.50k	0.0096% € 789.8k

7.7yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2HE sono considerati esperti (durata media dell'incarico 7.7 anni).

HealthEquity Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

HealthEquity, Inc. Announces CEO Changes, Effective January 6, 2025

Executive VP & CTO recently sold €853k worth of stock

HealthEquity, Inc., Annual General Meeting, Jun 27, 2024

HealthEquity, Inc. Announces the Termination of the Employment of Larry Trittschuh, Executive Vice President and Chief Security Officer

Executive VP & CTO recently sold €607k worth of stock

HealthEquity, Inc. Announces Change of CFO

Recent updates

HealthEquity, Inc. Announces CEO Changes, Effective January 6, 2025

HealthEquity, Inc. to Report Q3, 2025 Results on Dec 09, 2024

HealthEquity, Inc Launches HSAnswers

Executive VP & CTO recently sold €853k worth of stock

Second quarter 2025 earnings released: EPS: US$0.41 (vs US$0.12 in 2Q 2024)

HealthEquity, Inc. (NasdaqGS:HQY) announces an Equity Buyback for $300 million worth of its shares.

HealthEquity, Inc. to Report Q2, 2025 Results on Sep 03, 2024

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2025

First quarter 2025 earnings released: EPS: US$0.33 (vs US$0.048 in 1Q 2024)

HealthEquity, Inc. to Report Q1, 2025 Results on Jun 03, 2024

HealthEquity, Inc., Annual General Meeting, Jun 27, 2024

Full year 2024 earnings released: EPS: US$0.65 (vs US$0.31 loss in FY 2023)

HealthEquity, Inc. to Report Q4, 2024 Results on Mar 19, 2024

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ended January 31, 2024 and Fiscal Year Ending January 31, 2025

Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.019 loss in 3Q 2023)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2024 and 2025

HealthEquity, Inc. to Report Q3, 2024 Results on Dec 05, 2023

HealthEquity, Inc. (NasdaqGS:HQY) entered into a definitive agreement to acquire BenefitWallet’s Health Savings Account (HSA) portfolio from Conduent Business Services, LLC for $425 million.

Now 21% undervalued

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2024

Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.13 loss in 2Q 2023)

HealthEquity, Inc. to Report Q2, 2024 Results on Sep 05, 2023

HealthEquity, Inc. Announces the Termination of the Employment of Larry Trittschuh, Executive Vice President and Chief Security Officer

Executive VP & CTO recently sold €607k worth of stock

HealthEquity, Inc. Announces Change of CFO

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.16 loss in 1Q 2023)

HealthEquity, Inc. Provides Earnings Guidance for the Year Ending January 31, 2024

HealthEquity, Inc. to Report Q1, 2024 Results on Jun 05, 2023

Full year 2023 earnings released: US$0.31 loss per share (vs US$0.53 loss in FY 2022)

Now 22% undervalued after recent price drop

Independent Director recently sold €305k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023 and January 31, 2024

Third quarter 2023 earnings released: US$0.019 loss per share (vs US$0.06 loss in 3Q 2022)

HealthEquity, Inc. to Report Q3, 2023 Results on Dec 06, 2022

Independent Director recently sold €312k worth of stock

Independent Director recently sold €1.8m worth of stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.046 loss in 2Q 2022)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Healthequity, Inc. Elects Paul M. Black to Board of Directors and to Audit and Risk Committee and Talent, Compensation and Culture Committee

HealthEquity, Inc. to Report Q2, 2023 Results on Sep 06, 2022

HealthEquity, Inc. Announces Executive Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.032 loss in 1Q 2022)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

HealthEquity, Inc. to Report Q1, 2023 Results on Jun 06, 2022

HealthEquity, Inc., Annual General Meeting, Jun 23, 2022

HealthEquity, Inc. Expands Board of Directors

Insufficient new directors

HealthEquity, Inc. to Report Q4, 2022 Results on Mar 22, 2022

HealthEquity, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently bought €949k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently sold €462k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

Second quarter 2022 earnings released: EPS US$0.56 (vs US$0.002 loss in 2Q 2021)

Executive Vice President of Sales William Otten has left the company

Independent Director recently sold €647k worth of stock

Independent Director recently sold €290k worth of stock

Healthequity, Inc. Revises Earnings Guidance for the Fiscal Year Ending January 31, 2022

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

First quarter 2022 earnings released: US$0.032 loss per share (vs US$0.026 profit in 1Q 2021)

HealthEquity, Inc. (NasdaqGS:HQY) entered into a Custodial Transfer and Asset Purchase Agreement to acquire Health Savings Account Business of Fifth Third Bancorp from Fifth Third Bank, National Association for $60.8 million.

Full year 2021 earnings released: EPS US$0.12 (vs US$0.59 in FY 2020)

Full year 2021 earnings released: EPS US$0.12 (vs US$0.59 in FY 2020)

HealthEquity, Inc. (NasdaqGS:HQY) acquired Luum from Evan McCordick for $67.2 million.

HealthEquity, Inc. to Report Q4, 2021 Results on Mar 15, 2021

HealthEquity, Inc. has completed a Follow-on Equity Offering in the amount of $401.5 million.

New 90-day high: €64.00

Independent Director recently sold €202k worth of stock